CPI-613 (devimistat) + Hydroxychloroquine
Pancreatic Cancer
Key Facts
About Rafael Holdings
Rafael Holdings is a clinical-stage oncology company leveraging its expertise in cancer metabolism to develop innovative therapeutics. Its core asset, CPI-613, is a lipoate analog that disrupts key mitochondrial enzymes, inducing selective cancer cell death. The company is advancing CPI-613 through multiple clinical trials, primarily in combination regimens, and maintains a strategic focus on aggressive and rare cancers with high unmet need.
View full company profileTherapeutic Areas
Other Pancreatic Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| ARV-806 | Arvinas | Phase 1 |
| Ampligen® (rintatolimod) | AIM ImmunoTech | Early Access Program |
| SIMBs + Immunotherapy | Advanced Microbubbles | Pre-clinical |
| CLS-014 | CLS Therapeutics | Pre-clinical |
| SOMA Platform | Coherence Neuro | Pre-clinical |
| SON-1210 | Sonnet BioTherapeutics | Phase 1/2a |